ICD-9-CM diagnosis code (retired)
995.29 — Unspecified adverse effect of other drug, medicinal and biological substance
ICD-9-CM was replaced by ICD-10 on October 1, 2015. These are the ICD-10-CM equivalents from the CMS General Equivalence Mappings.
About ICD-9-CM 995.29
995.29 is an ICD-9-CM diagnosis code for unspecified adverse effect of other drug, medicinal and biological substance. ICD-9-CM was retired for U.S. claims on October 1, 2015, when ICD-10-CM took over.
The CMS General Equivalence Mappings translate it to 159 ICD-10-CM codes, such as T36.0X5A (Adverse effect of penicillins, initial encounter), T36.1X5A (Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter) and T36.2X5A (Adverse effect of chloramphenicol group, initial encounter). All of these are approximate matches, so review the record to pick the right one.
ICD-10-CM equivalents
- T36.0X5AAdverse effect of penicillins, initial encounterapproximate
- T36.1X5AAdverse effect of cephalosporins and other beta-lactam antibiotics, initial encounterapproximate
- T36.2X5AAdverse effect of chloramphenicol group, initial encounterapproximate
- T36.3X5AAdverse effect of macrolides, initial encounterapproximate
- T36.4X5AAdverse effect of tetracyclines, initial encounterapproximate
- T36.5X5AAdverse effect of aminoglycosides, initial encounterapproximate
- T36.6X5AAdverse effect of rifampicins, initial encounterapproximate
- T36.7X5AAdverse effect of antifungal antibiotics, systemically used, initial encounterapproximate
- T36.8X5AAdverse effect of other systemic antibiotics, initial encounterapproximate
- T36.95XAAdverse effect of unspecified systemic antibiotic, initial encounterapproximate
- T37.0X5AAdverse effect of sulfonamides, initial encounterapproximate
- T37.1X5AAdverse effect of antimycobacterial drugs, initial encounterapproximate
- T37.2X5AAdverse effect of antimalarials and drugs acting on other blood protozoa, initial encounterapproximate
- T37.3X5AAdverse effect of other antiprotozoal drugs, initial encounterapproximate
- T37.4X5AAdverse effect of anthelminthics, initial encounterapproximate
- T37.5X5AAdverse effect of antiviral drugs, initial encounterapproximate
- T37.8X5AAdverse effect of other specified systemic anti-infectives and antiparasitics, initial encounterapproximate
- T37.95XAAdverse effect of unspecified systemic anti-infective and antiparasitic, initial encounterapproximate
- T38.0X5AAdverse effect of glucocorticoids and synthetic analogues, initial encounterapproximate
- T38.1X5AAdverse effect of thyroid hormones and substitutes, initial encounterapproximate
- T38.2X5AAdverse effect of antithyroid drugs, initial encounterapproximate
- T38.4X5AAdverse effect of oral contraceptives, initial encounterapproximate
- T38.5X5AAdverse effect of other estrogens and progestogens, initial encounterapproximate
- T38.6X5AAdverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounterapproximate
- T38.7X5AAdverse effect of androgens and anabolic congeners, initial encounterapproximate
- T38.805AAdverse effect of unspecified hormones and synthetic substitutes, initial encounterapproximate
- T38.815AAdverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounterapproximate
- T38.895AAdverse effect of other hormones and synthetic substitutes, initial encounterapproximate
- T38.905AAdverse effect of unspecified hormone antagonists, initial encounterapproximate
- T38.995AAdverse effect of other hormone antagonists, initial encounterapproximate
- T39.015AAdverse effect of aspirin, initial encounterapproximate
- T39.095AAdverse effect of salicylates, initial encounterapproximate
- T39.1X5AAdverse effect of 4-Aminophenol derivatives, initial encounterapproximate
- T39.2X5AAdverse effect of pyrazolone derivatives, initial encounterapproximate
- T39.315AAdverse effect of propionic acid derivatives, initial encounterapproximate
- T39.395AAdverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounterapproximate
- T39.4X5AAdverse effect of antirheumatics, not elsewhere classified, initial encounterapproximate
- T39.8X5AAdverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounterapproximate
- T39.95XAAdverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounterapproximate
- T40.0X5AAdverse effect of opium, initial encounterapproximate
- T40.2X5AAdverse effect of other opioids, initial encounterapproximate
- T40.3X5AAdverse effect of methadone, initial encounterapproximate
- T40.4X5AAdverse effect of other synthetic narcotics, initial encounterapproximate
- T40.5X5AAdverse effect of cocaine, initial encounterapproximate
- T40.605AAdverse effect of unspecified narcotics, initial encounterapproximate
- T40.695AAdverse effect of other narcotics, initial encounterapproximate
- T40.7X5AAdverse effect of cannabis (derivatives), initial encounterapproximate
- T40.905AAdverse effect of unspecified psychodysleptics [hallucinogens], initial encounterapproximate
- T40.995AAdverse effect of other psychodysleptics [hallucinogens], initial encounterapproximate
- T41.5X5AAdverse effect of therapeutic gases, initial encounterapproximate
- T42.0X5AAdverse effect of hydantoin derivatives, initial encounterapproximate
- T42.1X5AAdverse effect of iminostilbenes, initial encounterapproximate
- T42.2X5AAdverse effect of succinimides and oxazolidinediones, initial encounterapproximate
- T42.3X5AAdverse effect of barbiturates, initial encounterapproximate
- T42.4X5AAdverse effect of benzodiazepines, initial encounterapproximate
- T42.5X5AAdverse effect of mixed antiepileptics, initial encounterapproximate
- T42.6X5AAdverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounterapproximate
- T42.75XAAdverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounterapproximate
- T42.8X5AAdverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounterapproximate
- T43.015AAdverse effect of tricyclic antidepressants, initial encounterapproximate
- T43.025AAdverse effect of tetracyclic antidepressants, initial encounterapproximate
- T43.1X5AAdverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounterapproximate
- T43.205AAdverse effect of unspecified antidepressants, initial encounterapproximate
- T43.215AAdverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounterapproximate
- T43.225AAdverse effect of selective serotonin reuptake inhibitors, initial encounterapproximate
- T43.295AAdverse effect of other antidepressants, initial encounterapproximate
- T43.3X5AAdverse effect of phenothiazine antipsychotics and neuroleptics, initial encounterapproximate
- T43.4X5AAdverse effect of butyrophenone and thiothixene neuroleptics, initial encounterapproximate
- T43.505AAdverse effect of unspecified antipsychotics and neuroleptics, initial encounterapproximate
- T43.595AAdverse effect of other antipsychotics and neuroleptics, initial encounterapproximate
- T43.605AAdverse effect of unspecified psychostimulants, initial encounterapproximate
- T43.615AAdverse effect of caffeine, initial encounterapproximate
- T43.625AAdverse effect of amphetamines, initial encounterapproximate
- T43.635AAdverse effect of methylphenidate, initial encounterapproximate
- T43.695AAdverse effect of other psychostimulants, initial encounterapproximate
- T43.8X5AAdverse effect of other psychotropic drugs, initial encounterapproximate
- T43.95XAAdverse effect of unspecified psychotropic drug, initial encounterapproximate
- T44.0X5AAdverse effect of anticholinesterase agents, initial encounterapproximate
- T44.1X5AAdverse effect of other parasympathomimetics [cholinergics], initial encounterapproximate
- T44.2X5AAdverse effect of ganglionic blocking drugs, initial encounterapproximate
- T44.3X5AAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounterapproximate
- T44.4X5AAdverse effect of predominantly alpha-adrenoreceptor agonists, initial encounterapproximate
- T44.5X5AAdverse effect of predominantly beta-adrenoreceptor agonists, initial encounterapproximate
- T44.6X5AAdverse effect of alpha-adrenoreceptor antagonists, initial encounterapproximate
- T44.7X5AAdverse effect of beta-adrenoreceptor antagonists, initial encounterapproximate
- T44.8X5AAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounterapproximate
- T44.905AAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounterapproximate
- T45.0X5AAdverse effect of antiallergic and antiemetic drugs, initial encounterapproximate
- T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounterapproximate
- T45.2X5AAdverse effect of vitamins, initial encounterapproximate
- T45.3X5AAdverse effect of enzymes, initial encounterapproximate
- T45.4X5AAdverse effect of iron and its compounds, initial encounterapproximate
- T45.515AAdverse effect of anticoagulants, initial encounterapproximate
- T45.525AAdverse effect of antithrombotic drugs, initial encounterapproximate
- T45.605AAdverse effect of unspecified fibrinolysis-affecting drugs, initial encounterapproximate
- T45.615AAdverse effect of thrombolytic drugs, initial encounterapproximate
- T45.625AAdverse effect of hemostatic drug, initial encounterapproximate
- T45.695AAdverse effect of other fibrinolysis-affecting drugs, initial encounterapproximate
- T45.7X5AAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounterapproximate
- T45.8X5AAdverse effect of other primarily systemic and hematological agents, initial encounterapproximate
- T45.95XAAdverse effect of unspecified primarily systemic and hematological agent, initial encounterapproximate
- T46.0X5AAdverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounterapproximate
- T46.1X5AAdverse effect of calcium-channel blockers, initial encounterapproximate
- T46.2X5AAdverse effect of other antidysrhythmic drugs, initial encounterapproximate
- T46.3X5AAdverse effect of coronary vasodilators, initial encounterapproximate
- T46.4X5AAdverse effect of angiotensin-converting-enzyme inhibitors, initial encounterapproximate
- T46.5X5AAdverse effect of other antihypertensive drugs, initial encounterapproximate
- T46.6X5AAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounterapproximate
- T46.7X5AAdverse effect of peripheral vasodilators, initial encounterapproximate
- T46.8X5AAdverse effect of antivaricose drugs, including sclerosing agents, initial encounterapproximate
- T46.905AAdverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounterapproximate
- T46.995AAdverse effect of other agents primarily affecting the cardiovascular system, initial encounterapproximate
- T47.0X5AAdverse effect of histamine H2-receptor blockers, initial encounterapproximate
- T47.1X5AAdverse effect of other antacids and anti-gastric-secretion drugs, initial encounterapproximate
- T47.2X5AAdverse effect of stimulant laxatives, initial encounterapproximate
- T47.3X5AAdverse effect of saline and osmotic laxatives, initial encounterapproximate
- T47.4X5AAdverse effect of other laxatives, initial encounterapproximate
- T47.5X5AAdverse effect of digestants, initial encounterapproximate
- T47.6X5AAdverse effect of antidiarrheal drugs, initial encounterapproximate
- T47.7X5AAdverse effect of emetics, initial encounterapproximate
- T47.8X5AAdverse effect of other agents primarily affecting gastrointestinal system, initial encounterapproximate
- T47.95XAAdverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounterapproximate
- T48.0X5AAdverse effect of oxytocic drugs, initial encounterapproximate
- T48.1X5AAdverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounterapproximate
- T48.205AAdverse effect of unspecified drugs acting on muscles, initial encounterapproximate
- T48.295AAdverse effect of other drugs acting on muscles, initial encounterapproximate
- T48.3X5AAdverse effect of antitussives, initial encounterapproximate
- T48.4X5AAdverse effect of expectorants, initial encounterapproximate
- T48.5X5AAdverse effect of other anti-common-cold drugs, initial encounterapproximate
- T48.6X5AAdverse effect of antiasthmatics, initial encounterapproximate
- T48.905AAdverse effect of unspecified agents primarily acting on the respiratory system, initial encounterapproximate
- T48.995AAdverse effect of other agents primarily acting on the respiratory system, initial encounterapproximate
- T49.0X5AAdverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounterapproximate
- T49.1X5AAdverse effect of antipruritics, initial encounterapproximate
- T49.2X5AAdverse effect of local astringents and local detergents, initial encounterapproximate
- T49.3X5AAdverse effect of emollients, demulcents and protectants, initial encounterapproximate
- T49.4X5AAdverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounterapproximate
- T49.5X5AAdverse effect of ophthalmological drugs and preparations, initial encounterapproximate
- T49.6X5AAdverse effect of otorhinolaryngological drugs and preparations, initial encounterapproximate
- T49.7X5AAdverse effect of dental drugs, topically applied, initial encounterapproximate
- T49.8X5AAdverse effect of other topical agents, initial encounterapproximate
- T49.95XAAdverse effect of unspecified topical agent, initial encounterapproximate
- T50.0X5AAdverse effect of mineralocorticoids and their antagonists, initial encounterapproximate
- T50.1X5AAdverse effect of loop [high-ceiling] diuretics, initial encounterapproximate
- T50.2X5AAdverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounterapproximate
- T50.3X5AAdverse effect of electrolytic, caloric and water-balance agents, initial encounterapproximate
- T50.4X5AAdverse effect of drugs affecting uric acid metabolism, initial encounterapproximate
- T50.5X5AAdverse effect of appetite depressants, initial encounterapproximate
- T50.6X5AAdverse effect of antidotes and chelating agents, initial encounterapproximate
- T50.7X5AAdverse effect of analeptics and opioid receptor antagonists, initial encounterapproximate
- T50.8X5AAdverse effect of diagnostic agents, initial encounterapproximate
- T50.995AAdverse effect of other drugs, medicaments and biological substances, initial encounterapproximate
- T50.A15AAdverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounterapproximate
- T50.A25AAdverse effect of mixed bacterial vaccines without a pertussis component, initial encounterapproximate
- T50.A95AAdverse effect of other bacterial vaccines, initial encounterapproximate
- T50.B15AAdverse effect of smallpox vaccines, initial encounterapproximate
- T50.B95AAdverse effect of other viral vaccines, initial encounterapproximate
- T50.Z15AAdverse effect of immunoglobulin, initial encounterapproximate
- T50.Z95AAdverse effect of other vaccines and biological substances, initial encounterapproximate
Common questions about 995.29
GEMs are a translation aid, not a substitute for coding from the record. The 2027 ICD-10 code set has changed since the last GEMs release in 2018. Page updated September 29, 2026.